What Are Malaysia NPRA’s License Requirements for Pharmaceutical Products?

Securing product approval from Malaysia’s Drug Control Authority (DCA) is a major milestone, but product registration alone is not sufficient for commercial supply. While product registration authorizes the product for the Malaysian market, commercial activities require the appropriate license from the National Pharmaceutical Regulatory Agency (NPRA).

Without the appropriate NPRA license, a registered pharmaceutical cannot legally be manufactured, imported, or distributed within the country. Achieving a seamless commercial launch requires product registration and NPRA licensing to be planned as coordinated workstreams within the overall market entry strategy.

This guide breaks down NPRA license types, application requirements, processing timelines, fees, and the specific triggers that require a renewal or a brand-new application. For support with NPRA licensing, pharmaceutical product registration, and market entry in Malaysia, contact Cisema today.

When Is an NPRA License Required?

An NPRA license is required before a company manufactures, imports, or wholesales registered pharmaceutical products in Malaysia. The specific license required depends on the supply chain activities undertaken.

Crucially, applicants must be entities registered in Malaysia. For Manufacturer’s and Import Licenses, the target pharmaceutical products must also already hold DCA registration.

This requirement is an important consideration for foreign companies, as a compliant Malaysian operating structure is required. Depending on thebusiness model, this may involve appointing a Malaysian Product Registration Holder (PRH) that can also undertake importing or other licensed activities.

For foreign businesses without a local footprint, partnering with an established PRH can simplify market entry by providing the local regulatory presence needed to support product registration and the relevant NPRA licensing activities.

The 3 Types of NPRA Licenses in Malaysia

Because NPRA issues activity-specific licenses, a company may require one or more licenses depending on how its products are manufactured, imported, or distributed.

Note: If your product portfolio includes Scheduled Poisons, additional requirements under the Poisons Act 1952 apply, including requirements relating to a Type A License and a registered pharmacist.

Preparing Your NPRA License Application

Selecting the right license type is only part of the process. The NPRA also requires documentation relating to the applicant’s premises, corporate status, and key personnel. Applications are submitted electronically via the NPRA’s QUEST system and must include the applicable supporting documentation.

Core Dossier Documentation

• Corporate Credentials: Official registration documents issued by the Companies Commission of Malaysia (SSM).
• Identity Verification: Passport or MyKad copies for the relevant authorized or responsible persons.
• Municipal Approvals: Valid local authority business licenses (PBT) covering every physical operating site.
• Storage Facility Permits: Local business permits for primary, secondary, and third-party logistics (3PL) facilities. (Note: Storage sites must reside in the same state as your primary premises, with combined allowances for Selangor, Kuala Lumpur, and Putrajaya).
• Compliance Checklists: Completed Lampiran B verification forms for new import and wholesale applications.
• Specialized Permits: A valid Type A (Wholesale) Poison License if handling Scheduled Poisons under the Poisons Act 1952.

Mandatory Personnel Requirements

In addition to the required documentation, applicants must designate the required Responsible Persons for the licensed activities. Two Responsible Persons must be designated, with at least one being a Malaysian citizen and readily contactable by the authorities.

NPRA License Fees and Validity

According to the NPRA July 2026 guideline, non-refundable application fees are structured as follows:

• Manufacturer’s License: RM1,000
• Import License: RM500
• Wholesaler’s License: RM500

NPRA licenses remain valid until 31 December of the year in which they are issued, unless an alternative validity period is specified in the license. Companies should initiate renewals prior to expiry to avoid disruption to commercial activities.

If you manage multiple pharmaceutical lines or operate through a local partner, ongoing license maintenance is as important as the initial submission. Rather than navigating renewal timelines alone, you can rely on Cisema to handle NPRA license renewals and regulatory updates as your Malaysian presence expands.

How Long Does an NPRA License Application Take? 

The NPRA’s client charter target the issuance of licenses within 15 working days. However, this timeframe should be regarded as a target rather than a guaranteed processing time.

The processing timeline applies once the following conditions have been met:

1. NPRA has received a complete application with no missing information
2. Compliance with applicable Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP) requirements has been verified
3. Any required facility inspections or premises assessments have been completed satisfactorily

If documentation is incomplete or an inspection identifies deficiencies, the NPRA may issue a Request for Information (RFI) through the QUEST online portal. Processing may pause until the applicant provides the requested information or addresses the identified deficiencies.

For this reason, companies should address premises, local authority, and GMP/GDP requirements before submitting their application.

When Is a New License Application Required?

Licenses are non-transferable. Certain changes to the licensed operation require a new license application rather than an update to the existing license.

The article lists:

• Physical facility relocations or corporate name changes
• Adding or moving primary or secondary storage premises
• Introducing Scheduled Poisons to your product line for the first time
• Re-establishing operations following a lapsed license
• Operational adjustments involving Time and Temperature Sensitive Products (TTSP)

Assessing the licensing implications before implementing operational changes can help avoid potential licensing issues.

Adding Pharmaceutical Products to an Existing NPRA License

Adding a pharmaceutical product does not necessarily require a new NPRA license.

If the underlying licensed operation remains unchanged, Manufacturer’s and Import License holders can submit an 'Additional Product List Application' via QUEST for newly registered, renewed, or amended products. The application must include the current license alongside relevant DCA approval documentation.

Planning NPRA Licensing for Pharmaceutical Market Entry

For foreign pharmaceutical companies, NPRA licensing should be planned alongside product registration rather than left until the final stage of launch.

Your roadmap should follow three key steps:

1. Appoint a Qualified Local PRH Early: Partner with an established Product Registration Holder in Malaysia to establish the required local regulatory presence without necessarily setting up a local subsidiary.
2. Coordinate product registration and licensing. Product registration is a prerequisite for the relevant licensing activities, but corporate, premises, and personnel requirements can be prepared in parallel.
3. Assess Facilities Prior to Submission: Conduct pre-licensing checks to ensure cold-chain and facility procedures meet applicable GDP requirements before an NPRA inspection, where required.

Integrating NPRA Licensing into Market Entry

For foreign pharmaceutical companies, obtaining an NPRA license involves more than completing an application. The local Malaysian entity, DCA product registration, licensed premises, responsible personnel, and GMP/GDP requirements all need to align before commercial activities can begin.

As an established Product Registration Holder (PRH) in Malaysia, Cisema supports pharmaceutical companies entering the Malaysian market with local regulatory representation, DCA product registration, NPRA license applications, GDP compliance, license renewals, and ongoing regulatory support.

For strategic guidance on introducing your pharmaceutical portfolio to the Malaysian market, reach out to Cisema’s regulatory specialists today.

Further Information

Explore Cisema’s pharmaceutical consulting services for Asia-Pacific.

References

• Guideline on Application of Manufacturer’s License, Import License and Wholesaler’s License for Registered Products (4th Edition, July 2026)

‍